Johnson & Johnson Announces $1 Billion Investment in Jacksonville Vision Operations
核心洞察
Johnson & Johnson will invest more than $1 billion to expand its ACUVUE (搜索) contact lens manufacturing, packaging, and distribution capabilities in Jacksonville, Florida.
The investment is part of the company's previously announced $55 billion U.S. manufacturing and R&D commitment through early 2029, with new facilities expected to be fully operational by 2028.
Jacksonville City Council approved a $12 million tax incentive package, with the city projecting a return on investment of $4.86 for every $1 in incentives.
Johnson & Johnson announced on June 15 a more than $1 billion investment to strengthen its Vision operations in Jacksonville, Florida, scaling U.S.-based manufacturing, packaging, and distribution capabilities to meet growing demand for its ACUVUE (搜索)-brand contact lenses.
"This is an investment in American manufacturing, in our workforce and in the long-term growth of this city, and it anchors our broader presence here in the state of Florida," said Joaquin Duato, chairman and CEO of Johnson & Johnson, during a media event held at the company's contact lens manufacturing facility at 7500 Centurion Parkway in Deerwood Park.
The announcement is part of Johnson & Johnson's previously disclosed $55 billion U.S. investment in manufacturing, research and development, and technology through early 2029. The company had not previously detailed specifics about its Jacksonville projects.
Facility Expansion and Timeline
The investment encompasses two major components: construction of a new supply chain facility in Northwest Jacksonville and installation of advanced manufacturing and packaging technologies at the existing Southside campus. Construction of the new distribution center, identified for Airport Commerce Center north of Jacksonville International Airport, is already underway with a target of being fully operational by 2028.
According to city legislation, the Northwest Jacksonville facility will be developed as part of the Airport Commerce Center industrial park, with plans for a building of up to approximately 1.08 million square feet on a 118.53-acre site. The project is being developed by The Suddath Cos. of Jacksonville.
"This investment reinforces our long-standing conviction that advanced manufacturing in the United States is essential to delivering healthcare solutions to patients at home and around the world," Duato said in a company release. "We are enhancing the resilience of our U.S. supply chain while helping more people see better and live better."
Economic Impact and Incentives
The Jacksonville City Council gave final approval on April 28 to a $12 million incentive package through a 16-0 vote. The incentives consist of two Recapture Enhanced Value (REV) Grants: a five-year, 60% grant of up to $1.5 million for facility construction and a five-year, 40% grant of up to $10.5 million for manufacturing equipment.
Under the agreement, Johnson & Johnson committed to a $550 million aggregate capital investment — $50 million for construction of the supply chain facility and $500 million for manufacturing equipment. The facility will add 10 jobs to the existing 3,500-employee workforce by the end of 2028. The REV grants are contingent on the company maintaining at least 1,964 jobs through the term of the grants.
Mayor Donna Deegan highlighted the financial rationale: "The return on investment with this company has been 5 to 1, so great return on investment for the city's investment in this project." A city staff report projected a return of $4.86 for every $1 in incentives, and noted the incentives "are a material factor in its decision to expand its operations here in Jacksonville" after the company conducted a search for alternative locations.
Manufacturing Scale and Legacy
Johnson & Johnson's Jacksonville operations manufacture approximately 1.7 billion ACUVUE (搜索) contact lenses annually, representing 90% of the brand's U.S. supply. The company said its Jacksonville operations have advanced eye health through innovative optical solutions, "helping to improve sight for more than 40 million patients in the U.S. and around the world."
The company established its Jacksonville presence in 1981 with the acquisition of Frontier Contact Lenses. The business was subsequently renamed Vistakon and operated under that name for three decades before transitioning to Johnson & Johnson Vision Care in the mid-2010s. In 2017, Johnson & Johnson Vision expanded beyond contact lenses with a $4.3 billion acquisition of Abbott Medical Optics, adding ophthalmic products for cataract surgery, laser refractive surgery, and consumer eye health.
"We have 11 sites across Florida that contribute approximately $6 billion to Florida's economy," Duato noted. "Here in Jacksonville, our vision business alone is projected to generate more than half a billion in economic activity over the next three years."
The company maintains more than 1.5 million square feet of manufacturing, research, distribution, and operations facilities across Florida. The surgical vision products from the Abbott Medical Optics acquisition are manufactured outside Jacksonville, though the overall Vision subsidiary remains headquartered in the city.
"When a global leader like Johnson & Johnson chooses to grow here, it sends a powerful message," Mayor Deegan said. "Jacksonville is a place where innovation thrives, talent succeeds, and investment delivers results."